Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Assess the Efficacy and Safety of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa Receiving Standard of Care Treatment

NCT07766005 is registered in ClinicalTrials.gov with Spyre Therapeutics, Inc. as lead sponsor.

NCT NCT07766005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07766005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Assess the Efficacy and Safety of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa Receiving Standard of Care Treatment
Lead sponsor
Spyre Therapeutics, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
June 30, 2028
Enrollment
150 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)